Isoniazid Dose Adjustment According to NAT2 Genotype (IDANAT2)

Status Terminated

Clinical Trial Summary

The study is conducted to compare safety and efficacy of isoniazid administered as an adjusted dose based on NAT2 (arylamine N-acetyltransferase type 2)genotype and as a standard dose.

The hypothesis is that the genotype-adjusted dose is superior to the standard dose with regard to hepatotoxicity and early treatment failure, respectively, in the group of slow and rapid acetylators of NAT2.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00571753
Study type	Interventional
Source	University of Cologne
Contact
Status	Terminated
Phase	Phase 3
Start date	June 2008
Completion date	February 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02736864` - Structural and Functional Repercussions of Pulmonary Tuberculosis Sequelae	N/A
Not yet recruiting	`NCT04055441` - A Study of Pattern of Presentation of Pulmonary Tuberculosis Patients Undergoing Treatment at Assiut University Hospital
Completed	`NCT02349841` - Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis	Phase 2
Completed	`NCT01927159` - Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers	Phase 1
Active, not recruiting	`NCT01691534` - Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)	Phase 2
Completed	`NCT00803322` - Improving Community Based Tuberculosis Care in Ethiopia	Phase 4
Completed	`NCT00834353` - Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis	N/A
Withdrawn	`NCT03277742` - Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz	N/A
Completed	`NCT00057434` - Vitamin A Therapy for Tuberculosis	Phase 3
Not yet recruiting	`NCT06192160` - Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis	Phase 2
Recruiting	`NCT06127641` - Rehabilitation of People With Post-tuberculosis Lung Disease	N/A
Recruiting	`NCT06058299` - Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis	Phase 2
Completed	`NCT04550832` - PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)	Phase 2
Completed	`NCT02912832` - Prospective Assessment of TBDx Feasibility	N/A
Completed	`NCT01215851` - Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z)	Phase 2
Recruiting	`NCT01503099` - Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease	N/A
Completed	`NCT04608955` - Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081	Phase 2
Recruiting	`NCT05046366` - Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.
Completed	`NCT05896930` - Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis	Phase 2
Completed	`NCT02279875` - A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)	Phase 2